7 results on '"Patel, Rajan K."'
Search Results
2. Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study
- Author
-
Green, Darren, Vassallo, Diana, Handley, Kelly, Ives, Natalie, Wheatley, Keith, Chrysochou, Constantina, Hegarty, Janet, Wright, Julian, Moss, Jon, Patel, Rajan K., Deighan, Chris, Webster, John, Rowe, Peter, Carr, Sue, Cross, Jenny, O’Driscoll, Jamie, Sharma, Raj, Mark, Patrick, and Kalra, Philip A.
- Published
- 2019
- Full Text
- View/download PDF
3. Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients.
- Author
-
Mark, Patrick B, Mangion, Kenneth, Rankin, Alastair J, Rutherford, Elaine, Lang, Ninian N, Petrie, Mark C, Stoumpos, Sokratis, and Patel, Rajan K
- Subjects
HEART failure ,LEFT ventricular dysfunction ,CHRONIC kidney failure ,DISEASE risk factors ,CHRONICALLY ill ,LEFT ventricular hypertrophy - Abstract
Chronic kidney disease (CKD) is a risk factor for premature cardiovascular disease. As kidney function declines, the presence of left ventricular abnormalities increases such that by the time kidney replacement therapy is required with dialysis or kidney transplantation, more than two-thirds of patients have left ventricular hypertrophy. Historically, much research in nephrology has focussed on the structural and functional aspects of cardiac disease in CKD, particularly using echocardiography to describe these abnormalities. There is a need to translate knowledge around these imaging findings to clinical outcomes such as unplanned hospital admission with heart failure and premature cardiovascular death. Left ventricular hypertrophy and cardiac fibrosis, which are common in CKD, predispose to the clinical syndrome of heart failure with preserved left ventricular ejection fraction (HFpEF). There is a bidirectional relationship between CKD and HFpEF, whereby CKD is a risk factor for HFpEF and CKD impacts outcomes for patients with HFpEF. There have been major improvements in outcomes for patients with heart failure and reduced left ventricular ejection fraction as a result of several large randomized controlled trials. Finding therapy for HFpEF has been more elusive, although recent data suggest that sodium-glucose cotransporter 2 inhibition offers a novel evidence-based class of therapy that improves outcomes in HFpEF. These observations have emerged as this class of drugs has also become the standard of care for many patients with proteinuric CKD, suggesting that there is now hope for addressing the combination of HFpEF and CKD in parallel. In this review we summarize the epidemiology, pathophysiology, diagnostic strategies and treatment of HFpEF with a focus on patients with CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Global longitudinal strain by feature-tracking cardiovascular magnetic resonance imaging predicts mortality in patients with end-stage kidney disease.
- Author
-
Rankin, Alastair J, Zhu, Luke, Mangion, Kenneth, Rutherford, Elaine, Gillis, Keith A, Lees, Jennifer S, Woodward, Rosie, Patel, Rajan K, Berry, Colin, Roditi, Giles, and Mark, Patrick B
- Subjects
CARDIAC magnetic resonance imaging ,CHRONIC kidney failure ,CAUSES of death ,MAGNETIC resonance imaging ,MORTALITY - Abstract
Background Patients with end-stage kidney disease (ESKD) are at increased risk of premature death, with cardiovascular disease being the predominant cause of death. We hypothesized that left ventricular global longitudinal strain (LV-GLS) measured by feature-tracking cardiovascular magnetic resonance imaging (CMRI) would be associated with all-cause mortality in patients with ESKD. Methods A pooled analysis of CMRI studies in patients with ESKD acquired within a single centre between 2002 and 2016 was carried out. CMR parameters including LV ejection fraction (LVEF), LV mass index, left atrial emptying fraction (LAEF) and LV-GLS were measured. We tested independent associations of CMR parameters with survival using a multivariable Cox model. Results Among 215 patients (mean age 54 years, 62% male), mortality was 53% over a median follow-up of 5 years. The median LVEF was 64.7% [interquartile range (IQR) 58.5–70.0] and the median LV-GLS was −15.3% (IQR −17.24 to −13.6). While 90% of patients had preserved LVEF (>50%), 58% of this group had abnormal LV-GLS (>−16%). On multivariable Cox regression, age {hazard ratio [HR] 1.04 [95% confidence interval (CI) 1.02–1.05]}, future renal transplant [HR 0.29 (95% CI 0.17–0.47)], LAEF [HR 0.98 (95% CI 0.96–1.00)] and LV-GLS [HR 1.08 (95% CI 1.01–1.16)] were independently associated with mortality. Conclusions In this cohort of patients with ESKD, LV-GLS on feature-tracking CMRI and LAEF was associated with all-cause mortality, independent of baseline clinical variables and future renal transplantation. This effect was present even when >90% of the cohort had normal LVEF. Using LV-GLS instead of LVEF to diagnose cardiac dysfunction in patients with ESKD could result in a major advance in our understanding of cardiovascular disease in ESKD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings.
- Author
-
Rutherford, Elaine, Weir-McCall, Jonathan, Patel, Rajan, Houston, J., Roditi, Giles, Struthers, Allan, Jardine, Alan, Mark, Patrick, Weir-McCall, Jonathan R, Patel, Rajan K, Houston, J Graeme, Struthers, Allan D, Jardine, Alan G, and Mark, Patrick B
- Subjects
KIDNEY disease diagnosis ,MAGNETIC resonance imaging ,KIDNEY diseases ,LEFT ventricular hypertrophy ,CHRONIC kidney failure ,PATIENTS ,CHRONIC kidney failure complications ,HEART disease complications ,DIAGNOSIS ,HEART ,HEART diseases ,MYOCARDIUM ,DISEASE incidence ,DISEASE prevalence ,RETROSPECTIVE studies - Abstract
Objectives: Left ventricular mass (LVM) at cardiac magnetic resonance imaging (CMR) is a frequent end point in clinical trials in nephrology. Trial participants with end stage renal disease (ESRD) may have a greater frequency of incidental findings (IF). We retrospectively investigated prevalence of IF in previous research CMR and reviewed their subsequent impact on participants.Methods: Between 2002 and 2006, 161 ESRD patients underwent CMR in a transplant assessment study. Images were used to assess LV mass and function. In the current study a radiologist reviewed the scans for IF. Review of patient records determined the subsequent clinical significance of IF.Results: There were 150 IF in 95 study participants. Eighty-four (56 %) were new diagnoses. One hundred and two were non-cardiac. Fifteen were suspicious of malignancy. There was a clinically significant IF for 14.9 % of the participants. In six cases earlier identification of an IF may have improved quality of life or survival.Conclusions: Without radiology support clinically important IF may be missed on CMR. Patients undergoing CMR in trials should be counselled about the frequency and implications of IF. Patients with ESRD have a higher prevalence of IF than reported in other populations. Nephrology studies require mechanisms for radiologist reporting and strategies for dealing with IF.Key Points: • Incidental findings on research cardiac magnetic resonance imaging can have significant consequences. • We considered incidental findings in historical renal cardiac resonance imaging clinical trials. • Incidental findings are common and important in the chronic kidney disease population. • Without radiology support, clinically significant incidental findings may be missed on imaging. • Study protocols, approvals and consent processes should take account of possible findings. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. Association of Left Atrial Volume With Mortality Among ESRD Patients With Left Ventricular Hypertrophy Referred for Kidney Transplantation.
- Author
-
Patel, Rajan K., Jardine, Alan G. M., Mark, Patrick B., Cunningham, Anthony F., Steedman, Tracey, Powell, Joanna R., McQuarrie, Emily P., Stevens, Kathryn K., Dargie, Henry J., and Jardine, Alan G.
- Abstract
Background Left ventricular hypertrophy (LVH) is common in patients with end-stage renal disease (ESRD) and an independent risk factor for premature cardiovascular death. Left atrial volume (LAV), measured using echocardiography, predicts death in patients with ESRD. Cardiovascular magnetic resonance (CMR) imaging is a volume-independent method of accurately assessing cardiac structure and function in patients with ESRD. Study Design Single-center prospective observational study to assess the determinants of all-cause mortality, particularly LAV, in a cohort of ESRD patients with LVH, defined using CMR imaging. Setting & Participants 201 consecutive ESRD patients with LVH (72.1% men; mean age, 51.6 ± 11.7 years) who had undergone pretransplant cardiovascular assessment were identified using CMR imaging between 2002-2008. LVH was defined as left ventricular mass index >84.1 g/m
2 (men) or >74.6 g/m2 (women) based on published normal left ventricle dimensions for CMR imaging. Maximal LAV was calculated using the biplane area-length method at the end of left ventricle systole and corrected for body surface area. Predictors CMR abnormalities, including LAV. Outcome All-cause mortality. Results 54 patients died (11 after transplant) during a median follow-up of 3.62 years. Median LAV was 30.4 mL/m2 (interquartile range, 26.2-58.1). Patients were grouped into high (median or higher) or low (less than median) LAV. There were no significant differences in heart rate and mitral valve Doppler early to late atrial peak velocity ratio. Increased LAV was associated with higher mortality. Kaplan-Meier survival analysis showed poorer survival in patients with higher LAV (log rank P = 0.01). High LAV and left ventricular systolic dysfunction conferred similar risk and were independent predictors of death using multivariate analysis. Limitations Only patients undergoing pretransplant cardiac assessment are included. Limited assessment of left ventricular diastolic function. Conclusions Higher LAV and left ventricular systolic dysfunction are independent predictors of death in ESRD patients with LVH. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
7. Are we overestimating left ventricular abnormalities in end-stage renal disease?
- Author
-
Mark, Patrick B., Patel, Rajan K., and Jardine, Alan G.
- Subjects
- *
MORTALITY , *CHRONIC kidney failure , *HYPERTROPHY , *ECHOCARDIOGRAPHY , *DOPPLER echocardiography , *CARDIAC imaging , *MAGNETIC resonance imaging - Abstract
The article looks at left ventricular abnormalities as a predictor of premature cardiovascular mortality in patients with end-stage renal disease (ESRD). Such abnormalities include the presence of left ventricular hypertrophy (LVH), left ventricular (LV) dilatation or LV systolic dysfunction (LVSD). The authors also looked at the use of both M-mode echocardiography, a 1D technique, and cardiac magnetic resonance (CMR) imaging and found that the former overestimates LV mass in ESRD.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.